A new peer reviewed paper has added weight to concerns about vaping and cancer risk. It says nicotine-based e-cigarettes are likely to be carcinogenic, with likely links to #lungcancer and oral cancer.

Find out what the evidence now says 👉 www.lungcancereuropenews.eu/news/can-vap...

#LCSM

We’re delighted to announce Dr Tom Newsom-Davis as keynote speaker at our 5th ALK+ UK National Conference. 💙

Join us in London 25–27 Sept for a weekend of expert talks, trusted information & time to connect with others in the ALK+ #LungCancer community #LCSM

www.alkpositive.org.uk/national-con...

If You're Newly Diagnosed with Lung Cancer, Read This What No One Tells You

younglungcancerinitiative.substack.com/p/if-youre-n... #lungcancer #lcsm #cancer

EMA recommends tarlatamab for relapsed extensive-stage small cell lung cancer — Lung Cancer Europe News EMA has recommended tarlatamab for adults with relapsed extensive-stage small cell lung cancer after platinum-based chemotherapy, marking an important step towards EU approval.

A positive EMA recommendation for tarlatamab marks an important step for relapsed extensive-stage SCLC in Europe. For people facing a disease with limited options after relapse, this matters. Now the focus must also be on fair & timely access. #LCSM

www.lungcancereuropenews.eu/news/ema-rec...

New AI Tool Predicts Whether Aggressive Small Cell Lung Cancer Will Respond to Treatment | OncLive A study shows that an AI pathology tool predicts whether a patient with extensive-stage small cell lung cancer will respond to platinum-based chemotherapy.

A study shows that an AI pathology tool predicts whether a patient with extensive-stage small cell lung cancer will respond to platinum-based chemotherapy. @roswellpark.bsky.social #lcsm #oncology
www.onclive.com/view/new-ai-...

CHMP Recommends Approval of First-Line Lurbinectedin Plus Atezolizumab Maintenance for ES-SCLC | OncLive Lurbinectedin plus atezolizumab received CHMP recommendation as first-line maintenance for ES-SCLC that has not progressed following induction therapy.

Lurbinectedin plus atezolizumab received CHMP recommendation as first-line maintenance for ES-SCLC that has not progressed following induction therapy.
#oncology #lcsm #SCLC
www.onclive.com/view/chmp-re...

ELCC is always an important meeting for us, but this year felt esp significant. For the 1st time, we launched our annual #LungCancer report during ELCC - a big change for us, & it felt like the right move.

It was also chance to introduce some of our new team & spend time with supporters. #LCSM

New March 2026 data from Cancer Research UK shows #lungcancer death rates in the UK have fallen by 22% over the past decade.

But the picture is very different for men and women. Over the last decade, lung cancer incidence rates rose by 8% in women, while falling by 13% in men.

#LCSM

A 🆕 article in Lung Cancer adds more detail from the ALINA trial, showing that adjuvant alectinib continued to show disease-free survival benefit over chemo across surgical subgroups in resected early-stage ALK+ #LungCancer. ALINA isn’t new, but this gives a closer look at who benefited. #LCSM

Dr Hirsch on Validation of an AI-Assisted PD-L1 Scoring Algorithm Against Blueprint Study Data in Lung Cancer | OncLive Fred R. Hirsch, MD, PhD, discusses research validating an AI-assisted PD-L1 scoring algorithm against original Blueprint study data in lung cancer.

WATCH: Fred R. Hirsch, MD, PhD, of @mountsinainyc.bsky.social discusses research validating an AI-assisted PD-L1 scoring algorithm against original Blueprint study data in lung cancer. #ELCC26 #lcsm #lungcancer #AI
www.onclive.com/view/dr-hirs...

Dr Girard on Updated Data From the PALOMA-2 Trial in EGFR-Mutant NSCLC | OncLive Nicolas Girard, MD, PhD, discusses updated data from the phase 2 PALOMA-2 trial (NCT05498428) that were presented at the 2026 European Lung Cancer Congress.

WATCH: Nicolas Girard, MD, PhD, of @institutcurie.bsky.social discusses updated data from the phase 2 PALOMA-2 trial that were presented at the 2026 European Lung Cancer Congress. #ELCC26 #ELCC2026 #lcsm #lungcancer
www.onclive.com/view/dr-gira...

CHMP Recommends Tarlatamab for Relapsed ES-SCLC | OncLive The EMA's CHMP recommends marketing authorization for tarlatamab monotherapy for ES-SCLC following relapse during or after platinum-based chemotherapy.

🫁 The European Medicines Agency’s CHMP has recommended granting marketing authorization for tarlatamab monotherapy in adults with ES-SCLC whose disease progresses during or after platinum-based chemotherapy.
#LungCancer #SCLC #lcsm #Oncology
www.onclive.com/view/chmp-re...

Calderasib-Based Therapy Drives High Responses in KRAS G12C–Mutant Metastatic NSCLC | OncLive Calderasib showed strong efficacy, with ORRs up to 72% in combination with pembrolizumab in patients with KRAS G12C–mutant metastatic NSCLC.

🫁Calderasib showed strong efficacy, with ORRs up to 72% in combination with pembrolizumab in patients with KRAS G12C–mutant metastatic NSCLC. @myesmo.bsky.social
#ELCC26 #lcsm
www.onclive.com/view/caldera...

Calderasib-Based Therapy Drives High Responses in KRAS G12C–Mutant Metastatic NSCLC | OncLive Calderasib showed strong efficacy, with ORRs up to 72% in combination with pembrolizumab in patients with KRAS G12C–mutant metastatic NSCLC.

🫁Calderasib showed strong efficacy, with ORRs up to 72% in combination with pembrolizumab in patients with KRAS G12C–mutant metastatic NSCLC. @myESMO
#ELCC26 #lcsm
www.onclive.com/view/caldera...

Surgical Planning in Early-Stage NSCLC Grows More Complex in the Biomarker Era | OncLive Biomarker testing has added another layer to surgical planning in early-stage NSCLC, necessitating tighter multidisciplinary coordination.

Jessica Donington, MD, MSCR, of @uchicagocancer.bsky.social disusses some of the logistical challenges that accompany the integration of biomarker testing into early-stage workflows. #oncology #lcsm #lungcancer
www.onclive.com/view/surgica...

ECOG Performance Status Emerges as Key Determinant of Adagrasib Activity in KRAS G12C–Mutant NSCLC | OncLive The ETOP ADEPPT trial met its primary end point with a 31% 12-week ORR with adagrasib in patients at least 70 years old with an ECOG PS of 0 or 1.

Adagrasib shows differentiated activity in KRAS G12C–mutant NSCLC 🔬

In ADEPPT, elderly patients with ECOG 0-1 saw meaningful, durable responses, while those with ECOG 2 had limited benefit despite some QOL gains.

Learn more: www.onclive.com/view/ecog-pe...

@myesmo.bsky.social #ELCC26 #lcsm

What did 140 people affected by Small Cell #LungCancer tell us about the impact of diagnosis on mental health?

We share findings tonight in Copenhagen at 18:15, alongside our 11th Report. Join us for the discussion & be among the first to pick up a copy. www.tickettailor.com/events/lungc... #LCSM

Setidegrasib Is Safe and Active in KRAS G12D-Mutated NSCLC | OncLive Setidegrasib yielded antitumor activity with a tolerable safety profile in KRAS G12D-mutated NSCLC.

Setidegrasib yielded antitumor activity with a tolerable safety profile in KRAS G12D-mutated NSCLC. @myesmo.bsky.social #ELCC26 #ELCC2026 #lcsm #oncology
www.onclive.com/view/setideg...

Osimertinib Plus Chemotherapy Doubles PFS in EGFR-, TP53-Mutant Advanced NSCLC | OncLive Osimertinib plus chemotherapy prolonged PFS vs osimertinib alone in patients with advanced NSCLC harboring concurrent EGFR and TP53 mutations.

Osimertinib plus chemotherapy prolonged PFS vs osimertinib alone in patients with advanced NSCLC harboring concurrent EGFR and TP53 mutations.
@myesmo.bsky.social
#ELCC26 #ELCC2026 #lcsm #oncology
www.onclive.com/view/osimert...

First-Line Serplulimab Plus Iza-Bren Is Deemed Tolerable and Has Antitumor Activity in ES-SCLC | OncLive Frontline iza-bren in combination with serplulimab was associated with a tolerable and manageable safety profile and elicited responses in ES-SCLC.

Frontline iza-bren in combination with serplulimab was associated with a tolerable and manageable safety profile and elicited responses in ES-SCLC. @myesmo.bsky.social #ELCC26 #ELCC2026 #lcsm #oncology
www.onclive.com/view/first-l...

Interesting to see Ben Solomon speak about early immune-based approaches in ALK+ lung cancer at #ELCC26.

Alongside TKIs, researchers are also looking at whether the immune system could be better engaged in ALK+ #lungcancer, including through ALK vaccines and ALK-specific T cell approaches. #LCSM

#ELCC26 is underway in Copenhagen.
We’re at stand D352 - come & say hi 👋

We’re talking mental health, lived experience, & what needs to change in #lungcancer care across Europe.

It’s not too late to get a ticket to our 11th Report Launch on Thurs eve www.tickettailor.com/events/lungc...

#LCSM

Ahead of ELCC 2026, we spoke with expert lung cancer clinicians to gain their insights into the most anticipated abstracts that will be presented at the meeting.
🔒 Sign up here to read: www.onclive.com/view/thoraci...
#oncology #ELCC2026 #lungcancer #NSCLC #lcsm

A poignant read in this weekend’s Guardian. Janis Chen writes about living with stage 4 #lungcancer and the in-between space that can come with it - ongoing treatment, uncertainty, fatigue, scanxiety, and trying to keep living around all of that. #LCSM

www.theguardian.com/society/2026...

Seatbelt Sign Is Off: How Soneesh Kothagundla Turned Airplanes Into A Life-Saving Movement Lung Cancer screening. How one high school student is creating a movement by talking to passengers on airplanes.

www.forbes.com/sites/toddno... #lungcancer #cancer #lcsm

I have stage four cancer – there will be no cure, but death isn’t necessarily imminent: this is how it feels to live in the long middle When you are cured, the world cheers; when you are dying, it mourns. But when you are simply maintaining, the world is at a loss

www.theguardian.com/society/2026... #lungcancer #cancer #lcsm

Thymic health and immunotherapy outcomes in patients with cancer - Nature A deep-learning approach applied to routine CT scans is used to quantify the health of the thymus in a cohort of patients with cancer, and shows that thymic function is associated with immunotherapy&n...

#AI on routine CT scans quantifies thymic health → predicts ICI outcomes in 3,476 patients across NSCLC, melanoma, renal & breast cancer — independent of PD-L1 and TMB.
Healthy thymus → ↑ TCR diversity → ↑ ICI efficacy. 🫁
#Immunotherapy #LungCancer #LCSM

🆙 #ELCC26 @myesmo.bsky.social
🔥Mini Oral session 2
☑️YL202/BNT326: HER3 ADC
🎯ORR across doses: 22.7-55.6%
🎯mPFS across doses: 2.8-10.0m
🎙️Dr. Haifeng Liu
🎙️Chair: Dr. Kersti Oselin, Dr. Mariano Provencio Pulla
📍NCT06107686
@oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social
🔥Mini Oral session 2
☑️SHR-A2009: HER3 ADC + aumolertinib
🎯ORR ≥2L/1L: 43.8-51.7%/77.4-66.7%
🎯mPFS ≥2L/1L: 8.1m/14.4m
🎙️Prof. Yi-Long Wu
🎙️Chair: Dr. Kersti Oselin, Dr. Mariano Provencio Pulla
📍NCT06092268
@oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social
🔥Mini Oral session 2
☑️TQB2922: EGFR/c-MET bispecific antibody +/- bev
🎯ORR mono vs. combi: 21.2%/64.7%
🎯Monotherapy TRAEs: rash 61.3%, IRR 50.7%
🎙️Dr. Jinhui Xue
🎙️Chair: Dr. Kersti Oselin, Dr. Mariano Provencio Pulla
📍NCT06188624
@oncoalert.bsky.social LARVOL #LCSM